| abstract |
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapy methods. In particular, the invention relates to immunotherapy for cancer. The present invention also relates to tumor-associated T-cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides (stimulating anti-tumor immune responses or in vitro stimulating T-cells and active pharmaceutical ingredients transferred to a patient's vaccine complex). Peptides that bind to major histocompatibility complex (MHC) molecules or peptides of the same type may also be targets for antibodies, soluble T cell receptors, and other binding molecules. |